Pfizer

YTD

ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

CEO

Albert Bourla

CEOAlbert Bourla

Employees

81,000

Employees81,000

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

1849

Founded1849

Employees

81,000

Employees81,000

PFE Key Statistics

Market cap

143.36B

Market cap143.36B

Price-Earnings ratio

13.35

Price-Earnings ratio13.35

Dividend yield

6.81%

Dividend yield6.81%

Average volume

51.51M

Average volume51.51M

High today

$25.30

High today$25.30

Low today

$24.97

Low today$24.97

Open price

$25.22

Open price$25.22

Volume

22.90M

Volume22.90M

52 Week high

$30.43

52 Week high$30.43

52 Week low

$20.92

52 Week low$20.92

PFE News

TipRanks 43m

Pfizer’s Sickle Cell Drug Fails to Meet Its Main Goal

Drugmaker Pfizer (PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage clinical trial called...

TipRanks 2h

Pfizer’s Promising Study on PF-07248144: A Potential Game-Changer in Cancer Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 2h

Pfizer’s Latest Study on HER2-positive Breast Cancer: Key Insights for Investors

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

Analyst ratings

54%

of 24 ratings

Buy

41.7%

Hold

54.2%

Sell

4.2%

More PFE News

TipRanks 3h

Pfizer’s PREVENAR 20 Vaccine Study: A Safety Investigation in Infants

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 3h

Pfizer’s Real-World Study on Abrocitinib: Implications for Investors

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 3h

Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer

Pfizer Inc ((PFE)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study. Elevate Your Investin...

TipRanks 3h

Pfizer’s New Clinical Study: A Step Forward in Cancer Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 3h

Pfizer’s New Phase 3 Study: A Potential Game-Changer in Breast Cancer Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

Seeking Alpha 5h

Pfizer fails in late-stage trial for sickle cell disease therapy

Healthcare Pfizer fails in late-stage trial for sickle cell disease therapy Aug. 15, 2025 10:24 AM ET Pfizer Inc. (PFE) Stock By: Dulan Lokuwithana, SA News Edi...

TipRanks 1d

Pfizer’s Phase 2 Study on Inotuzumab Ozogamicin: A Potential Game-Changer in Pediatric Leukemia Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.